Conditions which can result in impaired absorption, distribution, metabolism or excretion of the study treatment.
Presence of conditions that will interfere significantly with the absorption of drugs
Presence of active gastrointestinal (GI) disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of oral therapy (eg, ulcerative disease, uncontrolled nausea, vomiting, diarrhea ? Grade , and malabsorption syndrome).
Subject has any surgical or medical condition (active or chronic) that may interfere with drug absorption, distribution, metabolism, or excretion of the study drug, or any other condition that may place the subject at risk for such interference (for example, short bowel syndrome or inflammatory bowel disease).
Presence of active gastrointestinal (GI) disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of X-.
For patients who are treated with oral -azacitidine, any gastrointestinal disorder that would interfere with the absorption, distribution, metabolism or excretion of the study drug
Not be on agents known to alter rapamycin metabolism significantly
On agents known to alter rapamycin metabolism significantly
Any underlying condition that would significantly interfere with the absorption of an oral medication
Presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of drugs
Treatment with drugs that have the potential to interfere with metabolism or excretion of mibefradil
Any underlying condition that would significantly interfere with the absorption of an oral medication
Inability to swallow or retain oral medications or the presence of active GI disease or other conditions that will interfere significantly with the absorption, distribution, metabolism, or excretion of vorolanib
Any underlying condition that would significantly interfere with the absorption of an oral medication
Any underlying condition that would significantly interfere with the absorption of an oral medication
Gastrointestinal disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of oral therapy
Current disease or condition known to interfere with absorption, distribution, metabolism, or excretion of drugs, at the Investigator's discretion.
Presence of active gastrointestinal (GI) disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of the study drugs
History of GI perforation within  months prior to registration or presence of active GI disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of the study drugs
Presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption of drugs
History of malabsorption syndrome, disease significantly affecting gastrointestinal function or major resection of the stomach or small bowel that could affect absorption, distribution, metabolism or excretion of pazopanib
Presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption of drugs. If clarification is needed as to whether a condition will significantly affect absorption of drugs, contact the GSK medical monitor for guidance to enrol the subject;
History of malabsorption syndrome, disease significantly affecting gastrointestinal function or major resection of stomach or small bowel that could interfere with absorption, distribution, metabolism, or excretion of study drugs
EXPANSION COHORT ONLY: History of malabsorption syndrome, disease significantly affecting gastrointestinal function or major resection of stomach or small bowel that could interfere with absorption, distribution, metabolism, or excretion of study drugs
Presence of surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of study drug
Any underlying condition that would significantly interfere with the absorption of an oral medication
Presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption of drugs.
Presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of oral therapy (e.g. ulcerative disease, uncontrolled nausea, vomiting, grade ? diarrhea, and malabsorption syndrome).
Presence of gastrointestinal disease or any other condition that could interfere significantly with the absorption of the study drug.
Presence of active GI disease or other condition (e.g., small bowel or large bowel resection) that will interfere significantly with the absorption of drugs. If clarification is needed as to whether a condition will significantly affect absorption of drugs, contact the GSK Medical Monitor.
Presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption of drugs.
Presence of active gastrointestinal (GI) disease or other condition that will interfere significantly with the absorption of drugs.
Presence of active GI disease or other condition (e.g., small bowel or large bowel resection) that will interfere significantly with the absorption of drugs.
Presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption, distribution, metabolism or excretion of drugs.
Any underlying condition that would significantly interfere with the absorption of an oral medication
History or presence of hepatic or gastrointestinal diseases, or other condition that interferes with drug absorption, distribution, excretion or metabolism
Presence of active gastrointestinal (GI) disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of study medications.